866-997-4948(US-Canada Toll Free)

Anesthetic Effect - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Apr 2017

Category :

Diseases & Conditions

No. of Pages : 85 Pages

Anesthetic Effect - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect - Pipeline Review, H1 2017, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape.

Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of adverse reactions to anesthesia and drug allergies.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anesthetic Effect - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Anesthetic Effect (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anesthetic Effect (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 2, 1, 3, 15, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Anesthetic Effect (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Anesthetic Effect (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Anesthetic Effect (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anesthetic Effect (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anesthetic Effect (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anesthetic Effect (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anesthetic Effect (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anesthetic Effect (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Anesthetic Effect - Overview 6
Anesthetic Effect - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 13
Anesthetic Effect - Therapeutics Assessment 14
Assessment by Target 14
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Anesthetic Effect - Companies Involved in Therapeutics Development 21
4P Therapeutics LLC 21
Biolab Farmaceutica Ltda 21
Drawbridge Pharmaceuticals Pty Ltd 22
Expanesthetics Inc 22
Jiangsu Hengrui Medicine Co Ltd 23
Lee's Pharmaceutical Holdings Ltd 23
Lipicard Technologies Ltd 24
NanoMedex Pharmaceuticals Inc 24
Paion AG 25
Phosphagenics Ltd 25
Physica Pharma 26
Primex Pharmaceuticals Oy 26
Proteus SA 27
Sphaera Pharma Pvt Ltd 27
Taiwan Liposome Company Ltd 28
The Medicines Company 29
WEX Pharmaceuticals Inc 29
Anesthetic Effect - Drug Profiles 30
alphaxalone - Drug Profile 30
bupivacaine hydrochloride SR - Drug Profile 32
Carboetomidate - Drug Profile 33
gabafol - Drug Profile 34
HSK-3486 - Drug Profile 35
lidocaine hydrochloride - Drug Profile 36
lidocaine hydrochloride - Drug Profile 37
LT-1121 - Drug Profile 38
LT-1123 - Drug Profile 39
MDCO-700 - Drug Profile 40
Methoxycarbonyl Carboetomidate - Drug Profile 42
Methoxycarbonyl Etomidate - Drug Profile 43
midazolam hydrochloride - Drug Profile 45
neosaxitoxin - Drug Profile 46
PB-5109 - Drug Profile 48
PHY-301 - Drug Profile 49
propofol - Drug Profile 50
propofol - Drug Profile 51
propofol - Drug Profile 52
remimazolam - Drug Profile 53
remimazolam - Drug Profile 60
Small Molecule for General Anesthetic Effect - Drug Profile 61
Small Molecules for General Anesthetic Effect - Drug Profile 62
Small Molecules to Inhibit NMDA Receptor for Anesthesia - Drug Profile 63
SPR-819 - Drug Profile 64
Tetrodotoxin - Drug Profile 65
TLC-590 - Drug Profile 67
Anesthetic Effect - Dormant Projects 68
Anesthetic Effect - Discontinued Products 69
Anesthetic Effect - Product Development Milestones 70
Featured News & Press Releases 70
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 82
Disclaimer 83

List of Tables
Number of Products under Development for Anesthetic Effect, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Anesthetic Effect - Pipeline by 4P Therapeutics LLC, H1 2017
Anesthetic Effect - Pipeline by Biolab Farmaceutica Ltda, H1 2017
Anesthetic Effect - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H1 2017
Anesthetic Effect - Pipeline by Expanesthetics Inc, H1 2017
Anesthetic Effect - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
Anesthetic Effect - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
Anesthetic Effect - Pipeline by Lipicard Technologies Ltd, H1 2017
Anesthetic Effect - Pipeline by NanoMedex Pharmaceuticals Inc, H1 2017
Anesthetic Effect - Pipeline by Paion AG, H1 2017
Anesthetic Effect - Pipeline by Phosphagenics Ltd, H1 2017
Anesthetic Effect - Pipeline by Physica Pharma, H1 2017
Anesthetic Effect - Pipeline by Primex Pharmaceuticals Oy, H1 2017
Anesthetic Effect - Pipeline by Proteus SA, H1 2017
Anesthetic Effect - Pipeline by Sphaera Pharma Pvt Ltd, H1 2017
Anesthetic Effect - Pipeline by Taiwan Liposome Company Ltd, H1 2017
Anesthetic Effect - Pipeline by The Medicines Company, H1 2017
Anesthetic Effect - Pipeline by WEX Pharmaceuticals Inc, H1 2017
Anesthetic Effect - Dormant Projects, H1 2017
Anesthetic Effect - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Anesthetic Effect, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *